Education + Text Reminders for Parenting (in HPV Vaccination Uptake)
(Edtech-HPV Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if educational programs, with or without text reminders, increase HPV vaccination rates among Mexican-American children. The study compares two groups: one receives only educational materials, while the other receives both education and text reminders. It seeks Mexican-American parents or caregivers who primarily speak Spanish, have a child aged 11-17 who hasn't completed the HPV vaccine series, and use text messaging. Participants will also provide information on how COVID-19 has affected their daily lives. As an unphased trial, this study offers a unique opportunity to contribute to community health by exploring effective methods to increase vaccination rates.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this educational program and text messaging reminder are safe for increasing HPV vaccination uptake?
Research shows that the HPV vaccine is generally safe. Many studies have examined its safety and found that most people experience only mild side effects, such as pain at the injection site or a slight fever. Serious side effects are rare.
Studies also show that education and text message reminders can increase vaccination rates. These reminders safely inform and remind parents about the benefits of the HPV vaccine, with no known safety issues associated with receiving information through text messages.
Overall, evidence supports the safety of both the HPV vaccine and the reminder system.12345Why are researchers excited about this trial?
Researchers are excited about the Education + Text Reminders for Parenting approach because it combines parental education on the HPV vaccine with timely text message reminders to boost vaccination rates. Unlike the standard of care, which often relies solely on informational brochures or doctor recommendations, this strategy actively engages parents through digital communication. By providing ongoing reminders, it keeps the importance of the HPV vaccine top of mind, potentially leading to higher uptake and better protection against HPV-related diseases.
What evidence suggests that this trial's treatments could be effective in increasing HPV vaccination rates?
Research has shown that text message reminders can increase HPV vaccination rates. In this trial, one group of participants will receive both parental education on the HPV vaccine and text messaging reminders, while another group will receive only parental education. One study found that text messages and automated phone calls helped people receive their HPV vaccines on time. Another study showed that mobile health tools, such as text messages, improved vaccination rates. Combining digital education with text reminders also increased interest in vaccination, with various text message methods proving effective. Overall, these strategies have shown promise in helping people complete their HPV vaccinations.14678
Who Is on the Research Team?
Francesca Gany, MD, MPH
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for Spanish-speaking primary caregivers, aged 21-84, of children between 11 and 17 who haven't started or finished the HPV vaccine series. Participants must be Mexican or Mexican-American, own a cell phone with text messaging capabilities, and be willing to receive texts for the study. Those with serious psychiatric or cognitive impairments that affect consent or adherence are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Educational Intervention
Participants receive parental education on HPV vaccine and the vaccine's benefits, with or without a text messaging reminder system
Follow-up
Participants are monitored for vaccination completion and concerns related to COVID-19 impact
What Are the Treatments Tested in This Trial?
Interventions
- HPV Vaccine
- HPV Vaccine Education
- Text Messaging Reminder
HPV Vaccine is already approved in United States, European Union, Canada, Switzerland for the following indications:
- Prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
- Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
- Prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
- Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
- Prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
- Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
- Prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
- Prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Hackensack Meridian Health
Collaborator